Drugs / Meningococcal vaccine 134612
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00454909 | Apr → Oct 2007 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00390143 | Feb 2007 → May 2009 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal vaccine 134612 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00390143 ↗ |
| Modality | Vaccine | “GSK Biologicals' meningococcal vaccine 134612 up to 3.5 years after vaccination” NCT00390143 ↗ |
| Route | Intramuscular | “One intramuscular dose during the primary study” NCT00390143 ↗ |